For more than two decades, oncologists treating advanced pancreatic cancer have watched new drugs fail to move the survival needle in any meaningful way. That bleak track record is what makes topline results from Revolution Medicines so arresting: in a Phase 3 trial, patients who received the experimental drug daraxonrasib lived roughly twice as long as those given standard chemotherapy, a margin of benefit that pancreatic cancer research has never produced in a randomized controlled study.
The data, released in April 2026 from the global RASolute 302 trial, showed a median overall survival of 13.2 months for daraxonrasib compared with 6.7 months for chemotherapy. The hazard ratio for death was 0.40 with a p-value below 0.0001, indicating a statistically significant 60 percent reduction in the risk of dying. If the findings hold up under independent scrutiny, they could reshape how second-line pancreatic cancer is treated and mark a turning point in the long effort to target RAS, a family of cancer-driving proteins that scientists once considered undruggable.
Why pancreatic cancer has been so hard to treat
Pancreatic ductal adenocarcinoma, or PDAC, is the most common form of pancreatic cancer and one of the deadliest malignancies in medicine. The five-year survival rate for metastatic disease remains in the single digits. Since the late 1990s, when gemcitabine became the backbone of treatment, progress has been painfully incremental. The FOLFIRINOX regimen and nab-paclitaxel combinations extended survival by weeks to a few months in the first-line setting. In the second line, the best available option, a combination of nanoliposomal irinotecan with fluorouracil and leucovorin, produced a median overall survival of about 6.1 months in the landmark NAPOLI-1 trial.
Roughly 90 percent of pancreatic cancers carry mutations in the KRAS gene, making it the dominant oncogenic driver. But for decades, KRAS was considered undruggable because the protein’s smooth, pocket-free surface offered no obvious place for a small molecule to latch on. That began to change in 2021 when sotorasib became the first KRAS-targeted therapy approved by the FDA, though only for a specific mutation (G12C) found mainly in lung cancer. Daraxonrasib, also known as RMC-6236, takes a broader approach: it is designed to inhibit multiple RAS G12 variants, which is critical for pancreatic cancer because the most common KRAS mutations in PDAC are G12D and G12V, not G12C.
What the trial showed
Revolution Medicines disclosed the results through a Form 8-K filed with the SEC, a legally binding disclosure that exposes the company’s officers to liability if the reported data are materially misleading. The trial is registered under identifier NCT06625320 on the federal ClinicalTrials.gov registry, which describes it as a global, randomized, open-label Phase 3 study. Patients had metastatic PDAC and had already received one prior line of either 5-FU-based or gemcitabine-based therapy. The co-primary endpoints were progression-free survival and overall survival.
According to the company’s press release, the intent-to-treat analysis showed daraxonrasib patients living a median of 13.2 months versus 6.7 months on chemotherapy. Both progression-free survival and overall survival met their endpoints. The intent-to-treat framework is important: it includes all randomized patients regardless of whether they completed treatment, which reduces the chance that the survival advantage reflects only a self-selected group of patients who tolerated the drug unusually well.
To put the 6.5-month survival difference in context, it is larger than the gains produced by any prior drug approved for second-line pancreatic cancer. The control arm’s 6.7-month median is consistent with historical benchmarks, suggesting the comparison group performed as expected rather than unusually poorly, which would artificially inflate the experimental drug’s advantage.
What is still missing
The topline announcement leaves several critical questions unanswered, and patients, oncologists, and investors should weigh the excitement against what has not yet been disclosed.
Safety data. Revolution Medicines has not released adverse event rates from RASolute 302. Earlier-phase studies of RAS-pathway inhibitors have flagged side effects including skin toxicity, diarrhea, peripheral edema, and elevated liver enzymes. Without knowing how often serious toxicities occurred, how many patients needed dose reductions, and how many discontinued treatment, it is impossible to fully assess the drug’s benefit-risk balance.
Subgroup breakdowns. The press release notes that the trial enrolled patients with RAS G12 mutations but does not separate results by specific mutation subtype (G12D, G12V, G12R, and others), geography, age, or performance status. Different mutations can respond differently to targeted agents, and the 13.2-month median could mask meaningful variation. For clinicians deciding whom to treat, and for payers deciding what to cover, subgroup data will be essential.
Progression-free survival details. While PFS was reported as improved, the company has not shared exact medians, hazard ratios, or confidence intervals. PFS data help clarify whether the overall survival benefit stems from prolonged disease control on daraxonrasib or from differences in post-progression treatments, crossover rates, or other confounders.
Regulatory timeline. Neither the FDA nor the European Medicines Agency has publicly commented on daraxonrasib’s path forward. The company’s filings do not mention a submission timeline or whether breakthrough therapy or accelerated review designations are in play. For patients with a disease measured in months, the gap between promising data and an approved drug is not abstract.
How to weigh company-reported results
Every data point in this story originates from Revolution Medicines or from registries the company itself populated. The SEC filing, the press release, and the ClinicalTrials.gov entry are primary sources with legal weight, and the key statistics are internally consistent across all three. That consistency reduces the likelihood of simple errors or miscommunication about the main outcome.
But consistency is not the same as independent validation. No outside statistician has audited the analysis. No peer-reviewed journal has published the results. The trial’s open-label design, in which both patients and physicians knew which treatment was being given, can subtly influence clinical decisions such as how aggressively symptoms are managed or when scans are ordered. These biases matter less for overall survival, which is an objective endpoint, than for softer measures, but they are still worth noting.
It is also worth noting what topline announcements typically highlight: the clearest, most favorable results. Details that complicate the picture, such as imbalances in baseline patient characteristics, unexpected toxicity signals, or nuances in endpoint definitions, tend to surface only when full data are presented. The company’s own press release used the word “unprecedented” in its headline, a framing choice that reflects corporate optimism, not independent assessment.
What happens next
The full dataset is expected to be presented at a major oncology conference, most likely the American Society of Clinical Oncology annual meeting or a comparable venue later in 2026. That presentation will be the first opportunity for independent researchers to examine the trial’s statistical methods, patient-level outcomes, safety profile, and how issues like missing data and post-progression therapies were handled.
For patients and families facing metastatic pancreatic cancer now, the practical question is access. Daraxonrasib is not yet approved or commercially available. Whether Revolution Medicines will offer expanded access or compassionate use programs before a regulatory decision has not been announced. Patients interested in RAS-targeted therapy should discuss biomarker testing for KRAS mutations with their oncologists, as eligibility for any future treatment or ongoing trials will depend on molecular profiling of their tumors.
The results from RASolute 302 are, by any historical measure, remarkable for a disease that has humbled nearly every therapeutic strategy thrown at it. They are also, for now, preliminary. The distance between a topline press release and a treatment that changes clinical practice is measured in peer review, regulatory scrutiny, and real-world confirmation. Each of those steps will determine whether daraxonrasib delivers on what these early numbers suggest.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
